MDRNA, Inc. has entered into an agreement with Roche in which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed.
"We are pleased to have Roche recognize the value of our drug discovery platform," stated J Michael French, president and chief executive officer of MDRNA. "To have a portion of our platform in-licensed by Roche, a company with a significant effort in RNAi-based therapeutics, is a great testament to our intellectual property estate as well as the strong science being performed by our researchers. This agreement provides us the necessary resources to continue to pursue multiple, non-exclusive research collaborations, as well as future financing opportunities. We look forward to working with Roche to capitalize on the platform capability we are licensing to them as part of this agreement."
MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients.